Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
McKinsey
Citi
Deloitte
US Department of Justice
Merck
Baxter
Covington
Mallinckrodt
Federal Trade Commission

Generated: October 17, 2017

DrugPatentWatch Database Preview

ABBVIE Company Profile

« Back to Dashboard

What is the competitive landscape for ABBVIE, and what generic alternatives to ABBVIE drugs are available?

ABBVIE has ninety approved drugs.

There are eighty-nine US patents protecting ABBVIE drugs.

There are one thousand four hundred and forty-six patent family members on ABBVIE drugs in sixty-nine countries and one hundred and six supplementary protection certificates in fourteen countries.

Summary for Applicant: ABBVIE

International Patents:1446
US Patents:89
Tradenames:78
Ingredients:65
NDAs:90
Drug Master File Entries: (click here to view)1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
DIASONE SODIUM
sulfoxone sodium
TABLET, DELAYED RELEASE;ORAL006044-003Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Abbvie
TRICOR
fenofibrate
TABLET;ORAL021656-001Nov 5, 2004ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Abbvie Endocrine Inc
LUPRON DEPOT
leuprolide acetate
INJECTABLE;INJECTION020517-003Jun 17, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Abbvie
ANDROGEL
testosterone
GEL;TRANSDERMAL022309-003Sep 7, 2012AB2RXYesYes► Subscribe► SubscribeY► Subscribe
Abbvie
MIVACRON
mivacurium chloride
SOLUTION;INTRAVENOUS020098-004Jan 22, 1992RXYesNo► Subscribe► Subscribe► Subscribe
Abbvie
TRICOR
fenofibrate
TABLET;ORAL021656-002Nov 5, 2004ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Abbvie Inc
VIEKIRA XR
dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
TABLET, EXTENDED RELEASE;ORAL208624-001Jul 22, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906-001Oct 28, 2005RXYesYes► Subscribe► SubscribeY► Subscribe
Abbvie
ATROPINE AND DEMEROL
atropine sulfate; meperidine hydrochloride
INJECTABLE;INJECTION087847-001Nov 26, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Abbvie
ANDROGEL
testosterone
GEL;TRANSDERMAL022309-002Sep 7, 2012AB2RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Abbvie

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381-001Jul 28, 1997► Subscribe► Subscribe
Abbvie
KALETRA
lopinavir; ritonavir
CAPSULE;ORAL021226-001Sep 15, 2000► Subscribe► Subscribe
Abbvie Endocrine Inc
LUPRON DEPOT-PED
leuprolide acetate
INJECTABLE;INJECTION020263-006Jan 21, 1994► Subscribe► Subscribe
Abbvie Endocrine Inc
LUPRON DEPOT
leuprolide acetate
INJECTABLE;INJECTION020517-001Dec 22, 1995► Subscribe► Subscribe
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381-002Jul 28, 1997► Subscribe► Subscribe
Abbvie Endocrine Inc
LUPRON DEPOT
leuprolide acetate
INJECTABLE;INJECTION020011-001Oct 22, 1990► Subscribe► Subscribe
Abbvie
TARKA
trandolapril; verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020591-003Oct 22, 1996► Subscribe► Subscribe
Abbvie
TARKA
trandolapril; verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020591-004Oct 22, 1996► Subscribe► Subscribe
Abbvie
KALETRA
lopinavir; ritonavir
SOLUTION;ORAL021251-001Sep 15, 2000► Subscribe► Subscribe
Abbvie
KALETRA
lopinavir; ritonavir
SOLUTION;ORAL021251-001Sep 15, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ABBVIE drugs

Drugname Dosage Strength Tradename Submissiondate
lopinavir and ritonavir
Oral Solution80 mg/20 mg per mL
KALETRA
6/19/2014
testosterone
Gel1.62% (1.25 g and 2.5 g packets)
ANDROGEL
6/19/2013
ritonavir
Capsules100 mg
NORVIR
10/31/2012
testosterone
Gel1.62%
ANDROGEL
4/6/2012
ritonavir
Tablets100 mg
NORVIR
12/21/2010
clarithromycin
Extended-release Tablet500 mg
BIAXIN XL
12/6/2010
eprosartan mesylate
Tablets400 mg and 600 mg
TEVETEN
5/10/2010
fenofibrate choline
Delayed-release Capsules45 mg
TRILIPIX
9/2/2009
fenofibrate choline
Delayed-release Capsules135 mg
TRILIPIX
9/1/2009
cisatracurium besylate (multi-dose)
     Injection2 mg/mL, 10 mL vial
NIMBEX
8/12/2009
cisatracurium besylate (preserve free)
Injection2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial
NIMBEX
8/4/2009
lopinavir and ritonavir
Tablets100 mg/25 mg
KALETRA
12/23/2008
testosterone
Gel Metered-dose Pump1%
ANDROGEL
12/19/2008
paricalcitol
Injection0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials
ZEMPLAR
11/28/2008
paricalcitol
Capsules1 mcg and 2 mcg
ZEMPLAR
10/14/2008
paricalcitol
Capsules4 mcg
ZEMPLAR
8/25/2008
fenofibrate
Tablets48 mg
TRICOR
7/1/2008
trandolapril and verapamil hydrochloride
Extended-release Tablets1 mg/240 mg
TARKA
2/20/2008
trandolapril and verapamil hydrochloride
Extended-release Tablets2 mg/180 mg and 2 mg/240 mg
TARKA
11/9/2007
fenofibrate
Tablets145 mg
TRICOR
10/19/2007
trandolapril and verapamil hydrochloride
Extended-release Tablets4 mg/ 240 mg
TARKA
7/24/2007
hydrocodone bitartrate and ibuprofen
Tablets2.5 mg/200 mg
VICOPROFEN
2/24/2006
hydrocodone bitartrate and ibuprofen
Tablets5 mg/200 mg
VICOPROFEN
5/27/2005
divalproex sodium
Extended-release Tablets500 mg
DEPAKOTE ER
2/8/2005
trandolapril
Tablets1 mg, 2 mg and 4 mg
MAVIK
10/4/2004
divalproex sodium
Extended-release Tablets250 mg
DEPAKOTE ER
5/3/2004

Non-Orange Book Patents for Abbvie

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,592,903 Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate► Subscribe
6,162,443 Container for an inhalation anesthetic► Subscribe
8,332,661Method and apparatus for prevention of tampering, unauthorized use, and unauthorized extraction of information from microdevices► Subscribe
9,616,1352-iminobiotin formulations and uses thereof► Subscribe
7,198,795In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions► Subscribe
8,809,265Methods for treating HCV► Subscribe
8,853,176Methods for treating HCV► Subscribe
7,011,848Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor► Subscribe
9,617,303Sustained-release composition and method for producing the same► Subscribe
8,674,112Polymorph of a pharmaceutical► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Abbvie Drugs

Country Document Number Estimated Expiration
Bulgaria105665► Subscribe
Japan2013227314► Subscribe
Peru08352014► Subscribe
Guatemala200600295A► Subscribe
Austria493971► Subscribe
Mexico2009006653► Subscribe
United Kingdom2515941► Subscribe
Canada2828495► Subscribe
South Africa201203503► Subscribe
Canada2317126► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Abbvie Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2340029/01Switzerland► SubscribePRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: SWISSMEDIC 65301 25.11.2014
2015011Lithuania► SubscribePRODUCT NAME: PARITAPREVIRUM; REGISTRATION NO/DATE: EU/1/14.982 20150115
0729Netherlands► SubscribePRODUCT NAME: DASABUVIR OF ZOUT DAARVAN, WAARONDER DASABUVIR NATRIUMMONOHYDRAAT; REGISTRATION NO/DATE: EU/1/14/983 20150119
0443983/03Switzerland► SubscribePRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
90064-1Sweden► SubscribePRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
0150019 00156Estonia► SubscribePRODUCT NAME: PARITAPREVIIR;REG NO/DATE: EU/1/14/982 19.01.2015
C0026France► SubscribePRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220
13/044Ireland► SubscribePRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
2013 00053Denmark► SubscribePRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
15/011Ireland► SubscribePRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REGISTRATION NO/DATE: EU/1/14/982 20150115
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Fish and Richardson
Johnson and Johnson
Covington
Cantor Fitzgerald
Merck
Daiichi Sankyo
Cerilliant
Chubb
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot